| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545832 | BRAEBURN | Lipid depot formulations |
Jun, 2025
(1 year, 1 month from now) | |
| US8236755 | BRAEBURN | Opioid depot formulations |
Jul, 2026
(2 years from now) | |
| US8236292 | BRAEBURN | Liquid depot formulations |
Jan, 2027
(2 years from now) | |
| US11135215 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US11110084 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US10912772 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US9937164 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
Brixadi is owned by Braeburn.
Brixadi contains Buprenorphine.
Brixadi has a total of 7 drug patents out of which 0 drug patents have expired.
Brixadi was authorised for market use on 23 May, 2023.
Brixadi is available in solution, extended release;subcutaneous dosage forms.
Brixadi can be used as a method of administering an opioid maintenance treatment comprising buprenorphine. a method of treating opioid withdrawal using an opioid maintenance treatment comprising buprenorphine, a method of sustained delivery of buprenorphine to a human or non-human animal body. a method for treatment for opioid maintenance therapy, a method of administering an opioid maintenance treatment comprising buprenorphine, a method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction, a method of delivery of an opioid bioactive agent. a method of treatment or prophylaxis of a human or non-human animal for the treatment of opioid addiction and/or the symptoms of opioid withdrawal.
The generics of Brixadi are possible to be released after 26 July, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction; A method of delivery of an opioid bioactive agent. a method of treatment or prophyl...
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
BRIXADI family patents
